Recludix Pharma Reveals New Candidate Advancement Plan

Recludix Achieves Milestone with REX-8756, Triggering $50 Million Payment from Sanofi

Recludix Pharma has reached a significant milestone in its collaboration with Sanofi, marked by the successful completion of Good Laboratory Practice (GLP) toxicology studies for REX-8756. This achievement triggers a $50 million payment to Recludix, underscoring the progress and potential of their partnered program.

REX-8756: A Promising Compound

REX-8756 is recognized as a potent and selective allosteric inhibitor of STAT6. This mechanism of action holds promise for treating a variety of diseases driven by dysregulated STAT6 activity.

Potential Therapeutic Applications

• Inflammatory Diseases: REX-8756 may offer a novel approach to managing inflammatory conditions.
• Fibrotic Diseases: The compound’s mechanism could be beneficial in addressing fibrotic disorders.
• Other Immune-Mediated Diseases: Its targeted action on STAT6 could prove valuable in treating various immune-related ailments.

Collaboration with Sanofi

The collaboration between Recludix and Sanofi aims to leverage Recludix’s expertise in developing innovative therapies with Sanofi’s global resources and development capabilities. This partnership accelerates the advancement of REX-8756 and similar compounds.

Final Overview

The completion of GLP toxicology studies and the subsequent $50 million payment represent a crucial step forward in the development of REX-8756. With its potential to address a range of diseases, this compound holds significant promise for future therapeutic applications. The ongoing collaboration between Recludix and Sanofi will be instrumental in realizing this potential and bringing innovative treatments to patients in need.